Published on March 11, 2015

Indian pharma sector expects slowdown in exports for the fiscal year 2015. The reason behind his shortfall is delayed regulatory approvals and consolidation of pharmacy players in North America along with continuous depreciation of the currencies of emerging markets like Russia, Venezuela and Ukraine and many more.

According to the market research analyst, for Indian pharmaceutical companies the acceleration in domestic growth is a good sign and must reflect in their results for the quarter. In addition to it, as the growth in the US is projected to be moderately soft this ought to come in handy, in compare with the growth that one is accustomed to.

As per the report the Medical Council of India (MCI) has suspended the license of 15 neurologists for accepting foreign trip and hospitality from the Ahmedabad-based Intas Pharma. Recently the government plans to set up monitoring cells across the country to keep a watch on price movements, collections and availability of drugs. Source said that government is enthusiastic to work with Pharma industry and make suitable amendments in policies to enhance manufacturing activity.

Market players said that inclusion of the pharmaceuticals sector in the "Make in India" campaign has provided a unique opportunity to the industry to push its agenda of R&D, innovation and affordable healthcare for all.